Jul 2026· Cell Death and Differentiation· 0 citations· 57 references
Medicine
TL;DR
An integrated pan-cancer analysis of UPS protein dysregulation, prognostic associations, and mutation-driven remodeling shows that mRNA poorly predicts UPS protein abundance, that a defined set of E3 ligases is recurrently dysregulated across cancers, and that somatic mutations produce coherent UPS protein-quantitative trait locus signatures.
Abstract
Somatic mutations rewire the ubiquitin-proteasome system (UPS) to support tumor growth, but the proteome-wide consequences of cancer-driver alterations on UPS composition remain incompletely understood. Using harmonized proteogenomic data from up to 11 CPTAC cohorts, we performed an integrated pan-cancer analysis of UPS protein dysregulation, prognostic associations, and mutation-driven remodeling. We show that mRNA poorly predicts UPS protein abundance, that a defined set of E3 ligases is recurrently dysregulated across cancers, and that somatic mutations (most strikingly TP53 loss) produce coherent UPS protein-quantitative trait locus (pQTL) signatures. Two case studies (UBR5 and TRIM28) illustrate orthogonal modes of UPS rewiring: a mutation-driven axis in which TP53-mutant tumors elevate UBR5 to support replication stress tolerance, and a lineage-driven axis in which TRIM28 engages tissue-restricted regulatory networks with opposing prognostic effects in glioblastoma versus head and neck cancer. Each axis exposes context-specific therapeutic vulnerabilities, including sensitivity to DNA damage response inhibitors (UBR5-high) and lineage-specific drug responses (TRIM28-high). Together, these analyses define a mechanistic framework for how cancer-driver mutations reshape proteostasis through the UPS and nominate mutation- and lineage-defined dependencies for precision degrader therapy. The harmonized pan-tissue atlas and the UbiDash interactive resource that underpin parts of this analysis are reported in our companion paper [1].
Drug resistance remains a major barrier to durable targeted therapy, and cancer progression often reflects rewiring of signalling pathways that control protein stability. Dysregulation of the ubiquitin–proteasome system, including failure of degron-dependent substrate recognition, can stabilise oncogenic proteins, acce...
Jia-Xin Li, Shu-Han Liu, Lu Fu et al.· Frontiers in Cell and Develo...· 0 citations
By integrating protein structures with mutation data from 139,818 patients, this study generates detailed, functional maps of mutations for 173 cancer genes in 18+ tumor types, providing a proteo-genomic framework to characterize the effects of mutations in tumorigenesis and integrate them into workflows for clinical i...
D. Hyeon, Yu-Xiang Zhou, Wendy K. Chung et al.· Cancer Cell· 1 citation
Most genes produce multiple non-coding and coding RNA transcripts with potentially divergent biological functions, yet their contribution to cancer remains largely unexplored. Here, we built an integrated, transcript-resolution RNA-sequencing atlas of prostate cancer spanning 1,140 clinical samples from 10 independent...
Ji-Chang Zhang, Claudio Lorenzi, D. Bossi et al.· bioRxiv· 0 citations
RCBTB2 (RCC1 and BTB domain-containing protein 2), located at chromosome 13q14, is affected by deletion, amplification, expression change, or gene fusion across the cancers studied to date. The divergent directions of these alterations do not fit a tumor-suppressor model with a fixed direction of action. Here, genetic,...
Chuanhai Cai, Jianjun Du, Li-Ga Tu et al.· Frontiers in Oncology· 0 citations
The development of KRAS inhibitors is explored, highlighting the challenges due to KRAS’s ‘undruggable’ nature and the success of covalent inhibitors such as sotorasib for KRASG12C mutant cancers, and the ubiquitin–proteasome system is highlighted as key regulators of KRAS stability and signaling networks, providing co...
Yeonjoo Lee, Sua Hwang, Hyungkyung Shin et al.· Experimental and Molecular M...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.